Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

share-based compensation expenses, as well as legal,

facilities, and marketing expenses as compared with the prior-year

quarter.

-- Cash and cash equivalents were $97.7 million as of December 31, 2007,

compared with $44.2 million as of December 31, 2006 and $105.1

million as of September 30, 2007.

Financial Outlook for 2008

The Company anticipates 2008 cash expenses of approximately $40 million to $50 million, depending on the progress of various pre-clinical and clinical programs and the timing of its manufacturing scale up.

Conference Call

Halozyme management will host a pipeline update conference call tomorrow to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 888-463-4487 for domestic callers, or 706-679-5355 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation number 21378327. The conference call will be broadcast live over the Internet at http://www.halozyme.com and will be available for 30 days.

About HYLENEX

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in the formulation. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX recombinant if sensitization occurs. Hyaluronidase should not be applied directly to the cornea, and should not be injected around infected or ac
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... the Vice,President of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Dr. Yu worked at Pfizer Inc., where,she co-led ...
... Practices for Long-term Jatropha Development', the critical ... November 2007 position paper 'Sustainable Biodiesel Feedstock: ... It emphasizes the need to develop sustainability ... as a viable alternative energy source. Key ...
... BANNOCKBURN, Ill., July 10 Pinnacle Biologics, a,private, ... has entered into an agreement with pharmexx to ... in Western Europe. Terms of the,agreement were not ... Inc. stated, "We are,pleased to conclude this agreement ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... doesn,t end with the event itself. Blockage of blood flow ... With transplants scarce, half the people who live through a ... address this problem by engineering cardiac tissue to patch up ... Feiner under the supervision of Dr. Tal Dvir of ...
... September 23, 2013 It is often said that ... eliminate their attraction to the abused substance. New findings ... even long-term abstinence from cocaine does not result in ... currently trying to answer some of the ,chicken and ...
... Alliance, a nonprofit organization that focuses on local conservation and ... million award to address land use alteration as a significant ... The funding for the new program was awarded by ... (RDMA). Over 60 percent of emerging infectious diseases over ...
Cached Biology News:Putting the spring back in broken hearts 2Addiction: Can you ever really completely leave it behind? 2EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change 2
... uses include large-scale colony-counting and plaque-lifting, microbial ... TM automated colony picking and gridding ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
BD BioCoat Laminin 150 mm Culture Dishes...
...
Biology Products: